bluebird bio Inc BLUE.OQ BLUE.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The Somerville Massachusetts-based company is expected to report a 104.1% increase in revenue to $37.9 million from $18.57 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for bluebird bio Inc is for a loss of $3.69 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.6% in the last three months.
Wall Street's median 12-month price target for bluebird bio Inc is $8.00, above its last closing price of $3.95.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -5.13 | -5.98 | -2.95 | Beat | 50.6 |
Sep. 30 2024 | -6.65 | -7.29 | -6.20 | Beat | 14.9 |
Jun. 30 2024 | -9.96 | -8.33 | -8.40 | Missed | -0.8 |
Mar. 31 2024 | -8.83 | -8.81 | -7.20 | Beat | 18.3 |
Dec. 31 2023 | -13.01 | -13.24 | -15.60 | Missed | -17.8 |
Sep. 30 2023 | -13.45 | -13.50 | -13.20 | Beat | 2.2 |
Jun. 30 2023 | -14.37 | -14.31 | -13.40 | Beat | 6.4 |
Mar. 31 2023 | -5.37 | -7.40 | 4.20 | Beat | 156.8 |
This summary was machine generated May 5 at 13:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。